Plain-English translation of NCT06751329 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Ovarian Neoplasms research guide βPhase 1/2 β A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called , which is a type of antibody-drug conjugate designed to target cancer cells. The medication works by attacking two specific proteins found on cancer cells β MUC1 and HER3 β and delivering cancer-fighting drugs directly to tumors. Researchers are testing different doses of this medication to find the safest and most effective amount for people with advanced solid tumors.
Many people with advanced solid cancers like ovarian, prostate, colorectal, and pancreatic cancer have limited treatment options, and cancers often become resistant to current therapies. This trial is exploring whether the new treatment, which targets two cancer-specific proteins at once, might offer a more effective option for patients who have exhausted other treatments.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you join this trial, you will receive the medication as an intravenous infusion (into your vein) on Day 1, then repeat this infusion every 3 weeks. The study starts by testing lower doses in small groups of patients and gradually increases the dose as safety data is collected. You will have regular blood tests and imaging scans to monitor how your cancer responds and how your body tolerates the medication. The trial expects to enroll about 280 patients across multiple hospitals and medical centers.
AI-generated summary from trial data Β· Aug 20, 2026 Β· Not medical advice
United States
Australia